EXG202

EXG202 · Guangzhou Jiayin Biotech Ltd

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for EXG202, covering 2025-03-21 to 2025-09-17. Get the full timeline:

Most recent: Clinical Trial Update: Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD [Phase 1, Phase 2]